FOLH1 and prostate cancer: Here, we describe a case favorable for FT based on multiparametric MRI (mpMRI) and biopsy subsequently found to have clinically significant, contralateral prostate cancer based on PSMA PET/CT targeting of an MRI-invisible lesion.